One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Precigen, Inc.
PGEN · NMS · Healthcare · Biotechnology
Current price
$7.75
52-week range
$2.99 - $8.27
Market cap
$2.77B
Balance sheet
Distressed
-27.57x Concerning
Net debt $60.14M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 802.8% last year.
- Risk Return on equity was -837.1% last year — the company lost money on shareholders' equity.
What this company does
Precigen, Inc.
Precigen is a healthcare company developing advanced gene and cell therapies to fight diseases like cancer and autoimmune disorders (illnesses where the body's immune system attacks its own healthy cells). Since its treatments are still in the clinical trial stage (the required process of testing new medicines on people for safety and effectiveness), the company doesn't yet earn significant money from selling products. Its success depends entirely on these experimental therapies eventually getting approved for sale by health regulators.
How the company got here
Precigen was founded in 1998 as Intrexon Corporation, a company with a broad focus on synthetic biology. A key turning point came in early 2020 when Intrexon changed its name to Precigen, shifting its focus exclusively to healthcare and human gene and cell therapies. This strategic pivot involved selling off its non-healthcare businesses to concentrate on developing treatments for diseases with significant unmet needs. The company is now in the clinical stage, meaning its potential treatments are being tested in people, and it aims to bring these innovative therapies to market.
What it actually does
Precigen is a biopharmaceutical company that develops advanced medical treatments called gene and cell therapies. Think of these therapies as using a patient's own cells or specific genes as medicine to fight complex diseases like cancer, autoimmune disorders, and infectious diseases. The company is still in the development phase for most of its treatments, which means they are undergoing clinical trials (testing in humans to ensure they are safe and effective) before they can be widely sold. Precigen's main goal is to create highly targeted and precise medicines to help patients with serious illnesses.
AdenoVerse® Immunotherapy
This is one of Precigen's core technology platforms, which functions like a delivery system for gene-based medicines. It uses a modified, harmless virus (specifically, a type of adenovirus found in gorillas) to carry therapeutic genes into the body to stimulate a patient's immune system to fight diseases like cancer. A key advantage is that it can be administered multiple times to boost the immune response. This platform is the foundation for some of Precigen's leading drug candidates, including one for a rare airway tumor.
UltraCAR-T® Platform
This is another key technology platform focused on a type of cancer treatment called CAR-T cell therapy. This therapy involves taking a patient's own immune cells (T-cells), genetically engineering them in a lab to recognize and attack cancer cells, and then infusing them back into the patient. Precigen's UltraCAR-T platform is designed to be much faster than traditional methods, with the potential to manufacture these personalized cancer-fighting cells overnight. This speed could make the treatment more accessible to patients and potentially lower costs.
What management is betting on now
Precigen is currently focusing its resources on getting its first potential gene therapy, PRGN-2012, to market for the treatment of a rare airway disease called recurrent respiratory papillomatosis (RRP). The company is prioritizing the commercialization of this treatment, which could happen as early as 2025. To achieve this, they have streamlined their operations, which includes pausing some other clinical and preclinical programs to concentrate on this lead candidate. Their strategy also involves seeking strategic partnerships to help advance their other promising technologies, like the UltraCAR-T platform.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-23.61M
FY2024 Q4
$-9.27M
FY2025 Q1
$-16.95M
FY2025 Q2
$-19.94M
FY2025 Q3
$-29.46M
FY2025 Q4
$-23.48M
FY2026 Q1
$-44.09M
FY2026 Q2
$-18.20M
Revenue
$54.98M
Net income
$20.07M
Diluted EPS
0.05
Operating cash flow
$-17.81M
Free cash flow
$-18.20M
Fetching…
Sources
Revenue
$23.25M
Net income
$-7.93M
Diluted EPS
-0.02
Operating cash flow
$-43.83M
Free cash flow
$-44.09M
Fetching…
Sources
Revenue
$8.34M
Net income
$-23.50M
Diluted EPS
-0.04
Operating cash flow
$-23.46M
Free cash flow
$-23.48M
Fetching…
Sources
Revenue
—
Net income
$-146.34M
Diluted EPS
-1.06
Operating cash flow
$-29.07M
Free cash flow
$-29.46M
Fetching…
Sources
Revenue
$856.00K
Net income
$-26.64M
Diluted EPS
-0.09
Operating cash flow
$-18.98M
Free cash flow
$-19.94M
Fetching…
Sources
Revenue
$1.34M
Net income
$-54.15M
Diluted EPS
-0.18
Operating cash flow
$-16.32M
Free cash flow
$-16.95M
Fetching…
Sources
Revenue
$3.92M
Net income
$-19.73M
Diluted EPS
-0.05
Operating cash flow
$-8.24M
Free cash flow
$-9.27M
Fetching…
Sources
Revenue
—
Net income
$-23.98M
Diluted EPS
-0.09
Operating cash flow
$-22.73M
Free cash flow
$-23.61M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $7.75
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $60.1M. Interest coverage -27.6x.
Net debt
$60.14M
Interest coverage
-27.57x
Precigen, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
PGEN
BASELINE
Precigen, Inc.
Total debt $98.34M Interest coverage -27.57x This is the baseline the peer rows are being compared against.
Total debt $1.06B Interest coverage -17.25x Neither company has much profit cushion over interest right now.
Total debt $73.41M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $46.00M Interest coverage -38.64x Neither company has much profit cushion over interest right now.
Total debt $79.01M Interest coverage -192.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against PGEN
1 Reward
1 Risk
Rewards
-
Revenue grew 802.8% last year.
Risks
-
Return on equity was -837.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-35.23x
P/B
63.52x
P/S
32.37x
EV/EBITDA
-80.17x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
53.0%
Operating margin
41.2%
Net margin
-184.0%
ROE
-837.1%
ROA
-18.1%
Health
Liquidity and balance-sheet strength
Debt / equity
2.26x
Current ratio
4.58x
Quick ratio
3.76x
Total debt
$98.34M
Total cash
$38.21M
Growth
How the business has been compounding
Revenue TTM
$87.43M
Revenue 5Y CAGR
-25.8%
EPS TTM
-1.07
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-114.17M
Free CF TTM
$-89.83M
FCF margin
-102.7%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—